Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free XXXX - @entity6839 Fixed Combination Eyedrops.

@entity1 @entity725 @entity6839 @entity15438 @entity71622 @entity726
UNASSIGNED: Purpose. To compare the ocular pulse amplitude (OPA) lowering effects of preservative-free tafluprost and @entity15438 - @entity6839 fixed combination (DTFC) using dynamic contour tonometry. Methods. In total, 66 eyes of 66 @entity1 with normal tension @entity726 (NTG) (n = 34) or @entity725 ( @entity725 ) (n = 32) were included. @entity1 were divided into two groups: the preservative-free @entity71622 -treated group (n = 33) and the preservative-free DTFC-treated group (n = 33). Intraocular pressure (IOP) was measured using Goldmann applanation tonometry (GAT). OPA was measured using dynamic contour tonometry; corrected OPA (cOPA) was calculated at baseline and at 1 week and 1, 3, and 6 months after treatment. Results. After 6 months of treatment, tafluprost significantly reduced IOP (P < 0.001). The OPA lowering effects differed significantly between the two treatment groups (P = 0.003). The cOPA-lowering effect of tafluprost (1.09   mmHg) was significantly greater than that of DTFC (0.36   mmHg) after 6 months of treatment (P = 0.01). Conclusions. Tafluprost and DTFC @entity726 treatments provided marked OPA and IOP lowering effects. Tafluprost had a greater effect than DTFC; thus, this drug is recommended for @entity1 at risk of @entity726 progression, due to the high OPA caused by large fluctuations in IOP.
